Identity
- Security key
- 13798
- Ticker
- CRNX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2018-07-18
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- CRNX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $8,960,801,014.3
- Shares outstanding (class)
- 106,065,229
- Shares outstanding (weighted)
- 106,095,205
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 594
- Location
- SAN DIEGO, CA
- Homepage
- https://www.crinetics.com
- Description
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.